Healthcare provider profile · identity verified

Norma Martinez, MD

Family Practice · WHITTIER, CA · NPI 1780797837

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	716	218
Amlodipine Besylate	Amlodipine Besylate	368	113
Lisinopril	Lisinopril	334	104
Losartan Potassium	Losartan Potassium	326	91
Metformin Hcl	Metformin Hcl	319	105
Levothyroxine Sodium	Levothyroxine Sodium	283	76
Metoprolol Succinate	Metoprolol Succinate	253	67
Omeprazole	Omeprazole	227	90
Alendronate Sodium	Alendronate Sodium	222	66
Rosuvastatin Calcium	Rosuvastatin Calcium	190	64
Simvastatin	Simvastatin	183	54
Furosemide	Furosemide	152	48
Gabapentin	Gabapentin	134	53
Hydrochlorothiazide	Hydrochlorothiazide	132	42
Benazepril Hcl	Benazepril Hcl	121	39
Ibuprofen	Ibuprofen	120	40
Pioglitazone Hcl	Pioglitazone Hcl	111	32
Potassium Chloride	Potassium Chloride	111	33
Fluticasone Propionate	Fluticasone Propionate	110	46
Ibandronate Sodium	Ibandronate Sodium	101	31
Olmesartan Medoxomil	Olmesartan Medoxomil	98	28
Atenolol	Atenolol	95	28
Temazepam	Temazepam	92	22
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	88	26
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	85	24
Albuterol Sulfate Hfa	Albuterol Sulfate	83	35
Eliquis	Apixaban	81	20
Pantoprazole Sodium	Pantoprazole Sodium	80	28
Tramadol Hcl	Tramadol Hcl	79	17
Glipizide	Glipizide	77	23
Metoprolol Tartrate	Metoprolol Tartrate	67	21
Montelukast Sodium	Montelukast Sodium	66	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	65	18
Synthroid	Levothyroxine Sodium	64	18
Wixela Inhub	Fluticasone Propion/Salmeterol	63	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	19
Citalopram Hbr	Citalopram Hydrobromide	59	17
Famotidine	Famotidine	56	16
Hydralazine Hcl	Hydralazine Hcl	56	19
Carvedilol	Carvedilol	55	17
Meloxicam	Meloxicam	53	19
Escitalopram Oxalate	Escitalopram Oxalate	52	16
Lovastatin	Lovastatin	52	16
Valsartan	Valsartan	50	16
Baclofen	Baclofen	49	16
Glimepiride	Glimepiride	43	13
Pravastatin Sodium	Pravastatin Sodium	43	14
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	42	14
Meclizine Hcl	Meclizine Hcl	41	23
Sertraline Hcl	Sertraline Hcl	41	17
Duloxetine Hcl	Duloxetine Hcl	38	13
Januvia	Sitagliptin Phosphate	38	12
Allopurinol	Allopurinol	37	suppressed
Fenofibrate	Fenofibrate	37	11
Buspirone Hcl	Buspirone Hcl	36	19
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	34	14
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	34	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	32	12
Trulicity	Dulaglutide	31	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	29	suppressed
Diclofenac Sodium	Diclofenac Sodium	28	13
Dicyclomine Hcl	Dicyclomine Hcl	27	suppressed
Ezetimibe	Ezetimibe	27	12
Jardiance	Empagliflozin	26	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	26	suppressed
Azithromycin	Azithromycin	25	23
Clopidogrel	Clopidogrel Bisulfate	25	suppressed
Pioglitazone-Metformin	Pioglitazone Hcl/Metformin Hcl	25	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Glipizide Er	Glipizide	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Rybelsus	Semaglutide	23	suppressed
Metformin Hcl Er	Metformin Hcl	22	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Lansoprazole	Lansoprazole	21	suppressed
Mometasone Furoate	Mometasone Furoate	21	18
Trazodone Hcl	Trazodone Hcl	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	17
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	20	suppressed
Sildenafil Citrate	Sildenafil Citrate	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Labetalol Hcl	Labetalol Hcl	19	suppressed
Naproxen	Naproxen	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Xarelto	Rivaroxaban	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Benzonatate	Benzonatate	16	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	16	suppressed
Ketoconazole	Ketoconazole	16	13
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Methylprednisolone	Methylprednisolone	16	13
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Invokana	Canagliflozin	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Lactulose	Lactulose	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	11
Chlorthalidone	Chlorthalidone	12	suppressed
Dexlansoprazole Dr	Dexlansoprazole	12	suppressed
Febuxostat	Febuxostat	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Phentermine Hcl	Phentermine Hcl	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error